KALA Kala Pharmaceuticals Inc.

6.05
-0.03  -0%
Previous Close 6.08
Open 6.09
Price To Book 2.49
Market Cap 204,991,285
Shares 33,882,857
Volume 71,475
Short Ratio
Av. Daily Volume 198,940

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA approval announced August 23, 2018.
INVELTYS
Post‑operative inflammation and pain following cataract surgery
Phase 3 data released January 5, 2017 - both primary symptom endpoints met. Primary sign endpoint missed.
INVELTYS - STRIDE 1
Dry eye disease
PDUFA date August 15, 2019.
KPI‑121 0.25%
Dry eye disease
Phase 3 data due 4Q 2019.
KPI‑121 0.25% STRIDE 3
Dry eye disease